| LRRK2 inhibition attenuates microglial inflammatory responses MS Moehle, PJ Webber, T Tse, N Sukar, DG Standaert, TM DeSilva, ... Journal of Neuroscience 32 (5), 1602-1611, 2012 | 485 | 2012 |
| Abrogation of α-synuclein–mediated dopaminergic neurodegeneration in LRRK2-deficient rats JPL Daher, LA Volpicelli-Daley, JP Blackburn, MS Moehle, AB West Proceedings of the National Academy of Sciences 111 (25), 9289-9294, 2014 | 235 | 2014 |
| M1 and M2 immune activation in Parkinson’s disease: foe and ally? MS Moehle, AB West Neuroscience 302, 59-73, 2015 | 224 | 2015 |
| Leucine-rich repeat kinase 2 (LRRK2) pharmacological inhibition abates α-synuclein gene-induced neurodegeneration JPL Daher, HA Abdelmotilib, X Hu, LA Volpicelli-Daley, MS Moehle, ... Journal of Biological Chemistry 290 (32), 19433-19444, 2015 | 212 | 2015 |
| LRRK2 secretion in exosomes is regulated by 14-3-3 KB Fraser, MS Moehle, JPL Daher, PJ Webber, JY Williams, CA Stewart, ... Human molecular genetics 22 (24), 4988-5000, 2013 | 177 | 2013 |
| α-Synuclein fibril-induced inclusion spread in rats and mice correlates with dopaminergic Neurodegeneration H Abdelmotilib, T Maltbie, V Delic, Z Liu, X Hu, KB Fraser, MS Moehle, ... Neurobiology of disease 105, 84-98, 2017 | 170 | 2017 |
| Urinary LRRK2 phosphorylation predicts parkinsonian phenotypes in G2019S LRRK2 carriers KB Fraser, MS Moehle, RN Alcalay, AB West, LRRK2 Cohort Consortium, ... Neurology 86 (11), 994-999, 2016 | 135 | 2016 |
| Differential LRRK2 expression in the cortex, striatum, and substantia nigra in transgenic and nontransgenic rodents AB West, RM Cowell, JPL Daher, MS Moehle, KM Hinkle, HL Melrose, ... Journal of Comparative Neurology 522 (11), 2465-2480, 2014 | 130 | 2014 |
| Cholinergic system changes in Parkinson's disease: emerging therapeutic approaches NI Bohnen, AJ Yarnall, RS Weil, E Moro, MS Moehle, P Borghammer, ... The Lancet Neurology 21 (4), 381-392, 2022 | 90 | 2022 |
| The G2019S LRRK2 mutation increases myeloid cell chemotactic responses and enhances LRRK2 binding to actin-regulatory proteins MS Moehle, JPL Daher, TD Hull, R Boddu, HA Abdelmotilib, J Mobley, ... Human molecular genetics 24 (15), 4250-4267, 2015 | 79 | 2015 |
| Cholinergic projections to the substantia nigra pars reticulata inhibit dopamine modulation of basal ganglia through the M4 muscarinic receptor MS Moehle, T Pancani, N Byun, SE Yohn, GH Wilson, JW Dickerson, ... Neuron 96 (6), 1358-1372. e4, 2017 | 55 | 2017 |
| Allosteric activation of M4 muscarinic receptors improve behavioral and physiological alterations in early symptomatic YAC128 mice T Pancani, DJ Foster, MS Moehle, TJ Bichell, E Bradley, TM Bridges, ... Proceedings of the National Academy of Sciences 112 (45), 14078-14083, 2015 | 46 | 2015 |
| Leucine-rich repeat kinase 2 deficiency is protective in rhabdomyolysis-induced kidney injury R Boddu, TD Hull, S Bolisetty, X Hu, MS Moehle, JPL Daher, AI Kamal, ... Human molecular genetics 24 (14), 4078-4093, 2015 | 44 | 2015 |
| Unique functional and structural properties of the LRRK2 protein ATP-binding pocket Z Liu, RA Galemmo, KB Fraser, MS Moehle, S Sen, LA Volpicelli-Daley, ... Journal of Biological Chemistry 289 (47), 32937-32951, 2014 | 41 | 2014 |
| Roles of the M4 acetylcholine receptor in the basal ganglia and the treatment of movement disorders MS Moehle, PJ Conn Movement Disorders 34 (8), 1089-1099, 2019 | 40 | 2019 |
| Activation of the mGlu1 metabotropic glutamate receptor has antipsychotic-like effects and is required for efficacy of M4 muscarinic receptor allosteric modulators SE Yohn, DJ Foster, DP Covey, MS Moehle, J Galbraith, ... Molecular psychiatry 25 (11), 2786-2799, 2020 | 33 | 2020 |
| Regional differences in expression of β-tubulin isoforms in schizophrenia MS Moehle, RF Luduena, V Haroutunian, JH Meador-Woodruff, ... Schizophrenia research 135 (1-3), 181-186, 2012 | 32 | 2012 |
| Co-activation of metabotropic glutamate receptor 3 and beta-adrenergic receptors modulates cyclic-AMP and long-term potentiation, and disrupts memory reconsolidation AG Walker, DJ Sheffler, AS Lewis, JW Dickerson, DJ Foster, RK Senter, ... Neuropsychopharmacology 42 (13), 2553-2566, 2017 | 17 | 2017 |
| Discovery of the First Selective M4 Muscarinic Acetylcholine Receptor Antagonists with in Vivo Antiparkinsonian and Antidystonic Efficacy MS Moehle, AM Bender, JW Dickerson, DJ Foster, A Qi, HP Cho, ... ACS Pharmacology & Translational Science 4 (4), 1306-1321, 2021 | 16 | 2021 |
| Inhibition of LRRK2 kinase activity rescues deficits in striatal dopamine physiology in VPS35 p. D620N knock-in mice M Bu, J Follett, I Deng, I Tatarnikov, S Wall, D Guenther, M Maczis, ... npj Parkinson's Disease 9 (1), 167, 2023 | 1 | 2023 |
Andrew WestDuke University, UAB, Johns Hopkins, UCLA, Mayo ClinicVerified email at duke.edu
